TRIP13 and non-small cell lung carcinoma: Hence, combined treatment with MT and the TRIP13 inhibitor DZ0415 may lead to improved outcomes for NSCLC patients, while side effects may be only apparent in the male gonad due to the role of TRIP13 in meiosis [13].